Supplementary Information

The First Optimization of Novel, Potent, Selective PDE11A4 Inhibitors for Age-Related Cognitive Decline

Shams ul Mahmood^{1,5}, Mariana Lozano Gonzalez^{1,5+}, Sreedhar Tummalapalli^{1,5+}, Jeremy Eberhard², Judy Ly², Charles S. Hoffman², Michy P. Kelly³, John Gordon⁴, Dennis Colussi⁴, Wayne Childers⁴, David P. Rotella^{*1,5}

¹Department of Chemistry & Biochemistry, Montclair State University, Montclair, NJ 07043, ²Biology Department, Boston College, Chestnut Hill MA, 02467, ³Department of Anatomy & Neurobiology, School of Medicine, University of Maryland, Baltimore MD 21201, ⁴Moulder Center for Drug Discovery Research, Temple University, Philadelphia PA 19140. ⁵Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair NJ 07043

Index

- 1) Proton NMR pages S2-S17
- 2) HPLC pages S17-S32
- 3) Mass spectrum of compound 25 page S33
- 4) Expanded PDE selectivity of 14b and 23b pages S34
- 5) Protein expression and cell viability in cell-based assay pages S35-S36

Proton NMR and HPLC data of Final Compounds











































SAV: 0118000000

Date: 11/16/2022 5:32 AM



miniLC





12







1 $\frac{1}{2}$

		 - 10 C
100000	IN INCOME.	 £ ~
		10 m.
		Sec. 8 -

01.12.0

03.03.5 04:52.0 396.6

1016.7 35902.2

50.53

231.62 3874.36

1.1

 $\begin{array}{c} 2.7\\96.2\end{array}$





04.24.0

39638.6

96.7

4243.10



14a





14b

2	Compound	Rejoriton Time	Area	% Area	Holght
1 2		02.12.5 02.55.0	347.6 32596.9	1.0 99.0	79.46 4797.49

miniLC

- Method. 6 MINUTE ISOCRATIC 80% acre
- $Halch = I \, K$
- Sample. MSU-ISH-1-57
 - User: Goest SAV: 0118000000

 - Dete: 11/30/2022 4:24 AM





14c

n -	Compound	Retention Time	Агеа	% Area	Height
1		01:44.0	472.8	1.7	95.39
2		02.24.5	337.0	1.2	68.37
3		03:14.6	27394.2	97.0	4140.54



Method: 6 MINUTE ISOCRATIC 80% acn Batch: KJ Sample: MSU-TSR-1-54 User: Administrator SNA 011600000

Date: 11/29/2022 1:04 AM



14e

S. Compound Relevation % Area Height Area Time 95.65 02:13.0 816.6 1.0 1 $\frac{2}{3}$ 03.01.5 35370.5 96.74817.22 04.00.5 800.42.3131.12







4000 2000 \mathbf{O} 010062:00 050064.00 050006:00

14f





- Method. 6 MINUTE ISCORATIC 60% non
- **Batch** 167
- Sample: MSU-SMO-2-41
 - User: Guest S/N: 0118000000
 - Date: 11/12/2022 12:13 AM





14g

2	Compound	Retention Time	Area	% Area	Height
1		01:43.0	784.0	3.7	194.81
2		02:15.5	19772.4	96.3	3252.82

Method: 6 MINUTE ISOCRATIC 80% ace Batch: UY Sample: MSU-TSR-1-3 User: Guest SNI: 0116000000 Date: 11/30/2022 12.31 AM





Dete: 11/17/2022 12:30 AM



	Compound	Referition Time	Area	% Area	Height
1		02.12.5	439.1	1.5	103.29
2		02.28.5	31401.4	95.9	4878.04
3		02:55.0	449.7	1.4	87.15
4		03.29.5	166.6	1.2	77.55



18a

0 -

00:50

0100

Compound Referition Area % Area Height 8 Time 01:41.5 488.6 68.57 1.81 $\frac{1}{2}$ 01:56.5 1.7110.25 516.9 02:24.6 29756.396.74603.42

02:00

62:00

02:00

03:30

01:30



Method: 6 MINUTE ESOCIEATIC 60% acm Batch UY

Sample: MSU-ISH-1-49

User: Goest SN: 0118000000

Date: 11/30/2022 12:23 AM





18b

	Compound	Relection Time	Area	% Агеа	Height
1		01:52.0	239.3	0.9	58.27
2		02:30.0	634.7	3.3	199.78
3		03.21.6	24328.1	94.3	3822.70
4		04.750.0	407.5	1.6	565, 665,

miniLC



1 2





02:12.0

02.52.0

1642.4

33036.2

2.3

97.7

274.18

4736.27

18c

Method. 6 MINUTE ISOCRATIC 80% nom Batch: J Sample. MSU-SMG-1-180 Uner. Garel SAN: 0118000000 Date: 11/11/2022 11:36 PM



18d

2	Compound	Relention Time	Area	% Area	Height
1		01:44.0	438.7	1.4	90.47
2		02.21.0	00447 1.00	30.0	4040 / 110

02.59.0

04:11.0

1385.0

22693.3

5.6

91.4

265.61

2844.40

miniLC

Method: 6 MIMUTE RECORATIC 80% acc Batch: kj Sample: MSU-TSH-1-56 User: Coreal SW: 0114006000 Date: 11/29/2022 11:36 PM



1 2 3







25

==== Shimadzu LabSolutions Data Report ====

<Spectrum>

```
Line#:1 R.Time:11.817(Scan#:710)
MassPeaks:500
RawMode:Single 11.817(710) BasePeak:435(5905113)
BG Mode:None Segment 1 - Event 1
```



Expanded PDE Selectivity Screening 14b & 23b Table S-1 Inhibitory Effects of the Compounds on PDE Activities

	% Inhibition									
Inhibitors	PDE4A1A	PDE4B1	PDE4C1	PDE4D7	PDE7A1	PDE7B	PDE8A1	PDE9A2	PDE10A1	PDE10A2
SMQ-2-057 (23b), 1 μM	1	5	15	16	2	1	1	1	4	2
SMQ-2-057 (23b), 10 μM	24	14	34	33	2	51	11	2	10	3
SMQ-1-148 (14b), 1 µM	5	2	14	1	0	0	1	2	3	2
SMQ-1-148 (14b), 10 μM	8	4	36	5	8	3	7	1	5	6
Apremilast ~ 0.1 x IC ₅₀	9	10	8	8	-	-	-	-	-	-
Apremilast ~ 1 x IC50	50	54	41	53	-	-	-	-	-	-
Apremilast ~ 10 x IC ₅₀	93	94	87	93	-	-	-	-	-	-
BRL-50481 ~ 0.1 x IC ₅₀	-	-	-	-	9	-	-	-	-	-
BRL-50481 ~ 1 x IC50	-	-	-	-	51	-	-	-	-	-
BRL-50481 ~ 10 x IC ₅₀	-	-	-	-	93	-	-	-	-	-
Dipyridamole ~ 0.1 x IC ₅₀	-	-	-	-	-	10	10	-	-	-
Dipyridamole ~ 1 x IC ₅₀	-	-	-	-	-	48	50	-	-	-
Dipyridamole ~ 10 x IC50	-	-	-	-	-	86	89	-	-	-
Bay 73-6691 ~ 0.1 x IC ₅₀	-	-	-	-	-	-	-	8	-	-
Bay 73-6691 ~ 1 x IC ₅₀	-	-	-	-	-	-	-	52	-	-
Bay 73-6691 ~ 10 x IC ₅₀	-	-	-	-	-	-	-	90	-	-
Papaverine ~ 0.1 x IC ₅₀	-	-	-	-	-	-	-	-	11	9
Papaverine ~ 1 x IC ₅₀	-	-	-	-	-	-	-	-	54	51
Papaverine $\sim 10 \text{ x IC}_{50}$	-	-	-	-	-	-	-	-	91	95

Table S-2. PDE11A4 protein expression (normalized by Ponceau staining and expressed as a fold-change of DMSO) measured in drug-treated transiently-transfected HT-22 cell samples used in the PDE assay confirms that the decrease in PDE11A4 catalytic activity caused by these compounds is not explained by a reduction in expression of the protein itself.

	1	14b	25
DMSO	1.0±0	1.0 ± 0.14	1±0
0.1 μΜ	1.32±0.27	1.02±0.10	1.16±0.12
1 μΜ	1.21±0.29	1.10 ± 0.07	1.04 ± 0.17
10 µM	1.12±0.17	0.819±0.14	1.25±0.19
100 μΜ	0.94±0.03	0.78±0.10	1.19±0.12

Neither 1 (failed normality; ANOVA on Ranks: H(4)=1.04, P=0.4), 14b (F(4,15)=1.46, P=0.263) nor 25b (F(4,15)=0.56, P=0.697) significantly changed PDE11A4 protein expression. Data expressed as mean ±SEM.

Table S-3. The number of intact transiently transfected cells counted in a separate study of drug-treated HT-22 cells confirms that the decrease in PDE11A4 catalytic activity caused by these compounds is not explained by a loss of PDE11A4-expressing cells.

	1	14b	25
DMSO	100±21.9	63.8±4.6	73±5
0.1 μΜ	92±6.2	51.2±4.3	77.5±7.2
1 μΜ	86.5±12.7	53±3.7	92±7.3
10 μΜ	88.3±12.3	61.8±4.0	78.5±9.1
100 μM	76.84±10.1	61.5±2.7	71.5±2.4

Sample images for quanitification were taken using an inverted Leica microscope with a 10x objective. All cells within the field of view showing expression of the GFP-PDE11A4 recombinant protein were counted by an experimenter blind to treatment. Neither 1 (F(4,15)=0.38, P=0.817), 14b (F(5,18)=2.09, P=0.132) nor 25b (F(4,15)=1.50, P=0.251) significantly changed the total number of cells expressing PDE11A4 protein. Data expressed as mean ±SEM.